PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.2893
+0.0018 (0.63%)
At close: Dec 26, 2025, 4:00 PM EST
0.2836
-0.0057 (-1.97%)
After-hours: Dec 26, 2025, 7:17 PM EST
PAVmed Revenue
PAVmed had revenue of $5.00K in the quarter ending September 30, 2025, a decrease of -99.50%. This brings the company's revenue in the last twelve months to $29.00K, down -99.28% year-over-year. In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth.
Revenue (ttm)
$29.00K
Revenue Growth
-99.28%
P/S Ratio
160.72
Revenue / Employee
$744
Employees
39
Market Cap
8.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
| Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PAVM News
- 18 days ago - Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection - PRNewsWire
- 22 days ago - PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 5 weeks ago - Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree - PRNewsWire
- 6 weeks ago - PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 6 weeks ago - PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 - PRNewsWire